The site of apalutamide in the treatment of prostate cancer Letter to the Editor

Article Sidebar

PDF


Published: Sep 22, 2021
DOI: https://doi.org/10.24292/01.OR.124221921
Keywords:
apalutamide, prostate cancer, nonmetastatic, metastatic, CRPC, CSPC

Main Article Content

Kajetan Juszczak
1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of Urology Memorial Rydygier Hospital, Cracow, Poland. 3. Department of General and Oncological Urology, Nicolaus Copernicus Hospital, Torun, Poland
Tomasz Drewa
1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of Urology Memorial Rydygier Hospital, Cracow, Poland. 3. Department of General and Oncological Urology, Nicolaus Copernicus Hospital, Torun, Poland

Abstract

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Juszczak K, Drewa T. The site of apalutamide in the treatment of prostate cancer. OncoReview [Internet]. 2021Sep.22 [cited 2024Nov.25];11(4 (44):120-2. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1725
Issue
Vol 11 No 4 (44) (2021)
Section
SUPPORTIVE CARE IN ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mottet N, Cornford P, van den Bergh RCN et al. (2021). EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. http://uroweb.org/guideline/prostate-cancer (access: 8.09.2021).
2. Hong JH, Kim IY. Nonmetastatic castration-resistant prostate cancer. Korean J Urol. 2014; 55(3): 153-60.
3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180-92.
4. Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.
5. Smith MR, Saad F, Chowdhury S et al; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18.